SynthesisJournal of Korean medical science2014
Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?
Synthesis in Journal of Korean medical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Different dose of new generation proton pump inhibitors for the treatment ofInternational journal of immunopathology and pharmacologyPooled it
- Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.BMC gastroenterology · 2021Trial
- The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori.Medicine · 2020Trial
- Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment forGut microbes · 2020Trial
- Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments forWorld journal of gastroenterology · 2019Trial
- Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment forGut and liver · 2019Trial
- Trial
- Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.Gut and liver · 2016Trial
- Trial
- Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Antibiotic Resistance of Helicobacter pylori: Current Trends in Daegu-Kyungpook.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Korean Registry on the Current Management ofGut and liver · 2025Article
- Declining eradication rates ofWorld journal of gastroenterology · 2025Article
- Optimizing Treatment ofThe Korean journal of helicobacter and upper gastrointestinal research · 2024Article
- Article
- In Vitro Susceptibility and Synergistic Effect of Bismuth AgainstAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Resistance ofJournal of Korean medical science · 2024Review
- Comparison ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- [Can Sequential Therapy Replace Standard Triple Therapy asThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitor (PPI)-based triple therapy consisting of PPI, amoxicillin, and clarithromycin, is the recommended first-line treatment for Helicobacter pylori infection. However, the eradication rate of triple therapy has declined over the past few decades. We analyzed the eradication rate and adverse events of triple therapy to evaluate current practices in Korea. A comprehensive literature search was performed up to August 2013 of 104 relevant studies comprising 42,124 patients. The overall eradication rate was 74.6% (95% confidence interval [CI], 72.1%-77.2%) by intention-to-treat analysis and 82.0% (95% CI, 80.8%-83.2%) by per-protocol analysis. The eradication rate decreased significantly from 1998 to 2013 (P < 0.001 for both intention-to-treat and per-protocol analyses). Adverse events were reported in 41 studies with 8,018 subjects with an overall incidence rate of 20.4% (95% CI, 19.6%-21.3%). The available data suggest that the effectiveness of standard triple therapy for H. pylori eradication has decreased to an unacceptable level. A novel therapeutic strategy is warranted to improve the effectiveness of first-line treatment for H. pylori infection in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.